pathology of neoplasia
DESCRIPTION
Pathology of Neoplasia. Tumor – tissue mass Neoplasm – “ new growth ” , clonal expansion of cells with somatic mutations and variable autologous growth regulation Cancer – neoplasm with invasive or metastatic properties. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/1.jpg)
Pathology of Neoplasia
![Page 2: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/2.jpg)
Tumor – tissue mass
Neoplasm – “new growth”, clonal expansion of cells with somatic mutations and
variable autologous growth regulation
Cancer – neoplasm with invasive or metastatic properties
![Page 3: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/3.jpg)
Morphology of Neoplasia
![Page 4: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/4.jpg)
Malignant neoplasms invade normal tissues and cause mechanical disruption of normal function
gastric cancer
mesothelioma
![Page 5: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/5.jpg)
Superior vena cava syndrome
![Page 6: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/6.jpg)
primary invasive colon cancer
colon cancer metastases to liver
Invasion and metastasis of colon cancer
![Page 7: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/7.jpg)
tubular adenoma with in situ and early invasive cancer
![Page 8: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/8.jpg)
tubular adenoma with in situ and early invasive cancer
![Page 9: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/9.jpg)
“Benign tumors” are not invasive (leiomyoma of uterus)
![Page 10: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/10.jpg)
Lymph node metastasis
![Page 11: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/11.jpg)
Determinants of Cancer Metastatic Growth Sites
1. Pathways of lymphatic and vascular drainage
2. Molecular determinants for cell survival and
growth
Breast Cancer Colorectal Cancer
![Page 12: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/12.jpg)
Summary: Growth of Metastatic Cancer
• Spread of cancer cells to distant sites generally follows pathways of lymphatic and vascular drainage.
• Growth of cancer cells in metastatic site depends on ability of neoplastic cells to accommodate to new tissue (e.g., altered molecular composition of cell surface).
![Page 13: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/13.jpg)
Features of Benign and Malignant Tumors
• Well circumscribed, sometimes encapsulated
• Non-invasive• No associated
metastases• Organized tissue
structures
• Poorly circumscribed• Penetrates capsule if
present• Invasive into adjacent
tissues, lymphatics and vasculature
• Metastases• Poorly organized
aggregates of cells
Benign Malignant
![Page 14: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/14.jpg)
Features of Benign and Malignant Cells
• Low N/C ratio• Round nucleus, even
distribution of chromatin
• Maintenance of differentiation
• Uncommon mitoses
• High N/C ratio• Irregular nuclear
shape• Clumped chromatin• Prominent nucleoli• Loss of differentiation• Common mitoses,
often atypical
Benign Malignant
![Page 15: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/15.jpg)
Cellular Features of Benign and Malignant Cells
Benign Malignant
![Page 16: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/16.jpg)
Leiomyoma of Uterus
![Page 17: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/17.jpg)
Leiomyosarcoma of Uterus
![Page 18: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/18.jpg)
Follicular adenoma (left) with intact capsule
Follicular carcinoma (right) invading through capsule
![Page 19: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/19.jpg)
Nomenclature of tumors
Pathological features of benign and malignant tumors
Grading and staging cancer
Ancillary techniques to diagnose and classify neoplasms
![Page 20: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/20.jpg)
Nomenclature of Tumors
bile duct adenoma
tissue/ organ of origin
![Page 21: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/21.jpg)
Nomenclature of Tumors
bile duct adenoma
pattern of differentiation
![Page 22: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/22.jpg)
Nomenclature of Tumors
bile duct adenoma
benign
![Page 23: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/23.jpg)
Nomenclature of Tumors
adenocarcinoma
malignant, epithelial
![Page 24: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/24.jpg)
Nomenclature of Tumors
squamous cell carcinoma
malignant, epithelial
![Page 25: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/25.jpg)
Nomenclature of Tumors
leiomyosarcoma
malignant, mesenchymal
![Page 26: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/26.jpg)
-oma as a suffix for malignant tumors
• Lymphoma• Melanoma• Hepatoma (hepatocellular carcinoma)• Astrocytoma
![Page 27: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/27.jpg)
Common terms for epithelial tumors
• Epidermoid – a synonym for squamous cell• Adeno – glandular or ductal• Transitional cell – urothelial cells lining
bladder, renal pelvis, ureters
![Page 28: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/28.jpg)
Common terms for mesenchymal tumors
• Leiomyo – smooth muscle• Rhabdomyo – skeletal muscle• Chondro – cartilage• Osteo – bone (osteoid)• Fibro - fibrous
![Page 29: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/29.jpg)
Features of Benign and Malignant Tumors
• Well circumscribed, sometimes encapsulated
• Non-invasive• No associated
metastases• Organized tissue
structures
• Poorly circumscribed• Penetrates capsule if
present• Invasive into adjacent
tissues, lymphatics and vasculature
• Metastases• Poorly organized
aggregates of cells
Benign Malignant
![Page 30: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/30.jpg)
Features of Benign and Malignant Cells
• Low N/C ratio• Round nucleus, even
distribution of chromatin
• Maintenance of differentiation
• Uncommon mitoses
• High N/C ratio• Irregular nuclear
shape• Clumped chromatin• Prominent nucleoli• Loss of differentiation• Common mitoses,
often atypical
Benign Malignant
![Page 31: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/31.jpg)
Cellular Features of Benign and Malignant Cells
Benign Malignant
![Page 32: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/32.jpg)
Leiomyoma of Uterus
![Page 33: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/33.jpg)
Leiomyosarcoma of Uterus
![Page 34: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/34.jpg)
Follicular adenoma (left) with intact capsule
Follicular carcinoma (right) invading through capsule
![Page 35: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/35.jpg)
Tubular Adenoma of Colon
![Page 36: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/36.jpg)
Invasive Colon Cancer
![Page 37: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/37.jpg)
![Page 38: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/38.jpg)
Descriptive terms used in cancer nomenclature
• Cystic• Papillary• Polypoid • Mucinous• Scirrhous• Annular
![Page 39: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/39.jpg)
![Page 40: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/40.jpg)
![Page 41: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/41.jpg)
Neoplasms with intermediate levels of malignancy
• Borderline / Low malignant potential tumors (e.g., ovary)
• Carcinoid tumors (e.g., lung and gastrointestinal system)
![Page 42: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/42.jpg)
Pulmonary Carcinoid
![Page 43: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/43.jpg)
Pulmonary Carcinoid
![Page 44: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/44.jpg)
Clinical situation as a determinant of cancer diagnosis
• Site – smooth muscle tumor in uterus or in retroperitoneum/ mesentery.
• Gender – teratoma in woman (ovary) or in man (testis).
• Age – teratoma in testis of child or in testis of adult man
![Page 45: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/45.jpg)
Preinvasive neoplasia defies traditional definitions of benign and malignant tumors
Tubular adenoma of colonCarcinoma in situ (or severe dysplasia) of squamous mucosa
![Page 46: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/46.jpg)
In situ neoplasia • Atypical cells• Loss of maturation• Mitotic activity
![Page 47: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/47.jpg)
![Page 48: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/48.jpg)
![Page 49: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/49.jpg)
Examples of early (pre-invasive) neoplasia
moderate
unknown
variable
variable
risk for malignancy
yes
no
no
yes
“tumor”
atypical junctional
nevus
dysplasia of bronchial epithelium
dysplasia of cervix
adenoma of colon
neoplasm
![Page 50: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/50.jpg)
Examples of “benign tumors”
minimalyesintradermal nevus
of skin
minimalyesfibroadenoma
of breast
minimalyeslipoma
minimalyesleiomyoma
risk for malignancy“tumor”neoplasm
adenoma of colon yes variable
![Page 51: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/51.jpg)
Grading and Staging Cancer
![Page 52: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/52.jpg)
Grade: Loss of differentiation and atypical nuclear features Grade 1 – low grade
Grade 2 – intermediate gradeGrade 3 – high grade
![Page 53: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/53.jpg)
Grade 2 Grade 3
Grade 1
![Page 54: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/54.jpg)
Stage: size of tumor and extent of spread
Stage 0 – non-invasiveStage I – Stage II – Stage III - Stage IV – metastatic
Variable extent of invasion and lymph node metastases
![Page 55: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/55.jpg)
TNM staging of cancer
• T – size and extent of local invasion• N – lymph node metastases• M – metastases to other organs
![Page 56: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/56.jpg)
No evidence of primary tumor T0
Primary tumor < 3 cm, does not affect pleura or main bronchus
T1
Tumor > 3 cm or involves pleura or involves main bronchus
T2
Tumor involves chest wall or bronchus within 2 cm of trachea
T3
Tumor involves mediastinum, trachea, or esophagus, or has pleural effusion
T4
T Staging for Lung Cancer
![Page 57: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/57.jpg)
No evidence of primary tumor T0
Primary tumor < 2cmT1
Tumor > 2 cm, < 5 cmT2
Tumor > 5 cm T3
Tumor invades chest wall, or inflammatory carcinoma
T4
T Staging for Breast Cancer
![Page 58: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/58.jpg)
No lymph node metastasesN0
Involves ipsilaterial hilar or peribronchial nodes N1
Involves ipsilateral mediastinal nodes N2
Contralateral spread N3
N Staging for Lung Cancer
![Page 59: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/59.jpg)
No lymph node metastasesN0
Metastases to same-side movable nodes N1
Metastases to same-side fixed nodes N2
Metastases to internal mammary nodes N3
N Staging for Breast Cancer
![Page 60: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/60.jpg)
Overall Stage T Stage N Stage M Stage
Stage 0 Tis (In situ) N0 M0
Stage IA T1 N0 M0Stage IB T2 N0 M0
Stage IIA T1 N1 M0Stage IIB T2 N1 M0 T3 N0 M0Stage IIIA T1 N2 M0 T2 N2 M0 T3 N1 M0 T3 N2 M0Stage IIIB Any T N3 M0 T4 Any N M0Stage IV Any T Any N M1
Group Staging for Lung Cancer
![Page 61: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/61.jpg)
Years after diagnosis
Sur
viva
l
Stage IStage IIStage IIIaStage IIIbStage IV
Stage-specific survival for lung cancer1.0
0.8
0.6
0.4
0.2
1 2 3 4 5
![Page 62: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/62.jpg)
Ancillary techniques to diagnose and classify neoplasms
![Page 63: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/63.jpg)
Immunohistochemistry in diagnosis and classification of cancer
• Markers can help to recognize normal structures (e.g., basal cell layer)
• Some markers are differentially expressed in normal and benign tissues
• Markers can identify pattern of differentiation
![Page 64: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/64.jpg)
Basal cell marker p63(malignant glands lack staining)
Cancer marker α-methylacyl-CoA racemase(malignant glands stain positive)
![Page 65: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/65.jpg)
Cytokeratin 20 Cytokeratin 7
Colon Urinary tract Gastric Pancreas/ biliary
BreastLungPancreas/ biliary Ovary/ uterusSalivary gland
![Page 66: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/66.jpg)
Metastatic cancer in brain
CK 20 CK 7
![Page 67: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/67.jpg)
Prognostic and Predictive Markers for Cancer
• Pathological stage – most types of cancer• Pathological grade
– Gleason score (prostate cancer)• Biochemical and molecular markers
– Estrogen receptor (breast cancer)– Proliferation markers (many types of cancers)– Large numbers of other markers tested
![Page 68: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/68.jpg)
Estrogen Receptor in Breast Cancer•Favorable prognosis•Responds to anti-estrogen therapy
![Page 69: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/69.jpg)
Markers for early detection and monitoring cancer
• Proteins – PSA is prototype• RNA – usually inadequate stability• DNA – stable and potentially fingerprint of
neoplasia– Cancer specific mutations– Cancer specific methylation patterns
![Page 70: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/70.jpg)
Prostate-Specific Antigen (PSA)
• A protease that is made by prostate epithelial cells
• Has the best positive predictive value of any biochemical assay for cancer
0 – 2 ng/ml 1%2 – 4 ng/ml 15%4 – 10 ng/ml 25%> 10 ng/ml 50%
![Page 71: Pathology of Neoplasia](https://reader031.vdocument.in/reader031/viewer/2022033013/5681352a550346895d9c93a1/html5/thumbnails/71.jpg)
PSA screening for Prostate Cancer
• Mortality rate has declined in post-PSA era.• Comparison of incidence to mortality in
post-PSA era suggests over-diagnosis and over-treatment